High donor regulatory B cells (Bregs) and their rapid recovery are associated with protection from the development of acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation.
The study demonstrates that higher donor regulatory B cell levels improve outcomes in patients post allo-HSCT, indicating their protective role against acute GVHD.
Key Points
High donor regulatory B cell content correlates with reduced acute graft-versus-host disease risk after allo-HSCT.
Donors whose recipients developed aGVHD had significantly lower Breg percentages and absolute counts at 90 days.
Bregs recovered at slower rates in aGVHD (+) patients compared to those without aGVHD, affecting patient outcomes.
Infusion of grafts with higher median Breg content significantly decreased the risk of severe aGVHD, supporting their clinical importance.